NewEdge Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

NewEdge Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.48K	Sell	30 -20	-40%	-$4.71K	﹤0.01%	3554
2026 Q1	$9.98K	Buy	+50	New	+$9.89K	﹤0.01%	3401
2023 Q4	–	Sell	-2	Closed	-$120	–	3827
2023 Q3	$120	Hold	2	–	–	﹤0.01%	3357
2023 Q2	$144	Sell	2 -329	-99%	-$24.7K	﹤0.01%	3400
2023 Q1	$24.3K	Sell	331 -10	-3%	-$711	﹤0.01%	2268
2022 Q4	$556	Buy	+341	New	+$22.2K	﹤0.01%	3150

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NewEdge Advisors's LGND Position: Q2 2026 in Review

NewEdge Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 40% in Q2 2026, selling an estimated $4.71K and leaving 30 shares worth $9.48K. The position accounts for ﹤0.01% of the portfolio, ranked #3554.

NewEdge Advisors first reported a position in LGND in Q4 2022 and has held it in 6 quarters since. The position peaked at $24.3K in Q1 2023. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

NewEdge Advisors held 30 shares of Ligand Pharmaceuticals worth $9.48K as of Q2 2026.
NewEdge Advisors sold 20 Ligand Pharmaceuticals shares in Q2 2026, an estimated $4.71K.
Ligand Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3554 holding.
NewEdge Advisors first reported a position in Ligand Pharmaceuticals in Q4 2022 and has held it in 6 quarters since.
NewEdge Advisors's Ligand Pharmaceuticals position peaked at $24.3K in Q1 2023.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.